ALEC Live signaler | Maksimer profitt med Getagraph.com

SELG 137817 min ago

@ $6.07

Utstedt: 13 feb 2024 @ 21:46

Avkastning: -10.38%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -2.10 %

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

Stats
Dagens volum	529 526
Gjennomsnittsvolum	600 068
Markedsverdi	524.33M
EPS	$0 ( 2024-05-09 )
Neste inntjeningsdato	( $-0.500 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.91
ATR14	$0.00700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	500 000	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Buy	98 533	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	98 533	Common Stock
2024-03-19	Altmeyer Mark	Buy	41 250	Common Stock
2024-03-19	Altmeyer Mark	Buy	19 420	Stock Option (right to buy)

INSIDER POWER
-25.53
Last 100 transactions
Buy: 2 784 515 \| Sell: 4 159 752

Volum Korrelasjon

Lang: 0.25 (neutral)

Kort: 0.71 (moderate)

Signal:(73.417) Neutral

Alector Inc Korrelasjon

10 Mest positive korrelasjoner
AEHR	0.894
NEOG	0.893
VMAR	0.891
BROG	0.89
EHTH	0.889
LCID	0.885
EVOK	0.876
RVNC	0.876
NDRA	0.874
TXG	0.871

10 Mest negative korrelasjoner
BSCO	-0.847
ESTA	-0.83
NESR	-0.823
OXSQ	-0.82
PTMN	-0.817
LPCN	-0.811
SFBC	-0.81
KRUS	-0.808
IMPP	-0.805
AEAE	-0.802

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Alector Inc Korrelasjon - Valuta/Råvare

-0.23
( neutral )

0.11
( neutral )

0.00
( neutral )

0.52
( weak )

Alector Inc Økonomi

Annual	2023
Omsetning:	$97.06M
Bruttogevinst:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2023
Omsetning:	$97.06M
Bruttogevinst:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2022
Omsetning:	$133.62M
Bruttogevinst:	$125.15M (93.66 %)
EPS:	$-1.620

FY	2021
Omsetning:	$207.09M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.467

Financial Reports:

No articles found.

Alector Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.